Why us?  Why us? please click dropdown
4.8/5 out of 3,500+ reviews
Regulated: CQC Registered | 1-5796078466
  • Verified Content: Approved by the Women’s Health Clinic Clinical Team.
  • Educational Use: This is not a substitute for professional medical advice, diagnosis, or treatment.
  • Clinical Assessment: Individual suitability is determined by a clinician; results may vary.
  • MEDICAL EMERGENCY:

    If you need urgent help, use NHS 111. For a life-threatening emergency, call 999.

 Author  Find more about the author
Dr Farzana Khan

Dr Farzana Khan

Verified

Dr Farzana Khan qualified as an MD from the University of Copenhagen in 2003. She has worked in dermatology and obstetrics & gynaecology across the North of England and completed her MRCGP (CCT, 2013) and the Diploma of the Faculty of Sexual & Reproductive Health (2013). Her clinical focus is vaginal health—including dryness/GSM, sexual function concerns, lichen sclerosus, and comfort or volume changes. She offers careful assessment, discusses medical and conservative options first, and considers selected regenerative or aesthetic treatments where appropriate. Dr Farzana also trains clinicians as a KOL/Trainer with Neauvia, Asclepion Laser, and RegenLab (since 2023). Ongoing CPD includes IMCAS, CCR, ACE and expert training in women’s intimate fillers, PRP, and polynucleotide injectables. Her approach is simple: clear explanations, realistic expectations, and shared decision-making. Authored and medically reviewed by Dr Farzana Khan.

MD MRCGP DFFP
Was this answer helpful?
Rate Dr Farzana's explanation
faq Vaginal Laxity (postnatalmenopause support)

When can I resume sex after laser/RF or injectables?

When can I resume sex after laser/RF or injectables? Most women wait until any spotting and soreness settle and the entrance feels comfortable with a generous, compatible lubricant—typically 2–7 days after superficial injectables (e.g., hyaluronic acid boosters, PRP, polynucleotides) and 5–14 days after vaginal laser or radiofrequency. If you’re peri-/post-menopausal with genitourinary syndrome of menopause (GSM), optimising moisturiser and (if acceptable) local oestrogen improves comfort. Educational only. Results vary. Not a cure.

Clinical Context

Who typically resumes sooner? Women having superficial injectables (HA boosters, PRP, polynucleotides) without significant bruising or sting often resume comfortable penetrative sex within 2–7 days using generous lubricant and low-pressure positions. Those with good pelvic floor relaxation cues progress fastest.

Who benefits from a longer pause? After laser/RF, after childbirth, or where GSM causes marked dryness or “paper-cut” fissures, allow up to 5–14 days and prioritise moisturiser and (if acceptable) local oestrogen. Pain-dominant/overactive pelvic floor patterns may need extra down-training before resuming.

Next steps now. Keep a simple diary for 2–4 weeks: sting (0–10), micro-tear/spotting days, ease at first penetration/speculum, and confidence. If comfort isn’t improving, pause, revert to foundations and book review rather than pushing on.

Evidence-Based Approaches

NHS (patient-friendly): Practical guidance on pelvic floor exercises and management of vaginal dryness after menopause underpins conservative care before and after procedures.

NICE menopause guideline (NG23): Recommends vaginal moisturisers/lubricants and considering low-dose local vaginal oestrogen for symptomatic GSM, with shared decision-making about ongoing use. NICE NG23.

NICE interventional guidance (IPG645): Transvaginal laser for urogenital atrophy should be used with special arrangements for consent and audit owing to limited evidence—hence a cautious, outcomes-tracked approach after laser. NICE IPG645.

Cochrane Library: Reviews support pelvic floor muscle training for symptom and quality-of-life gains and highlight heterogeneity/short follow-up for energy devices, guiding realistic post-procedure expectations. Cochrane Library – pelvic floor & GSM.

BNF/MHRA: For medicines/devices used around intimate care, UK sources outline product governance, cautions and reporting routes—useful when planning aftercare and return to activity. BNF · MHRA.